文献速递肝病

使用ELF检测、FIB-4和NAFLD纤维化评分对人群进行肝病筛查

Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease.
PubMed 文献 · J Hepatol · 2023-04-21

该前瞻性研究纳入3378名普通人群及酒精相关或非酒精性脂肪性肝病(ALD/NAFLD)高危人群,以瞬时弹性成像(TE)为参考标准,比较增强肝纤维化(ELF)检测与FIB-4指数、NAFLD纤维化评分(NFS)的筛查性能。结果显示ELF假阳性率(11%)显著低于FIB-4(35%)和NFS(45%),且诊断晚期纤维化的AUROC为0.85,优于FIB-4的0.73和NFS的0.66。作者认为ELF单独或联合FIB-4可减少无效转诊而不漏诊真实病例。

要点

  • ELF假阳性率11%,显著低于FIB-4的35%和NFS的45%,假阴性率<8%。
  • ELF诊断晚期纤维化AUROC 0.85,优于FIB-4的0.73和NFS的0.66。
  • FIB-4后对不确定病例行ELF的策略假阳性8%、假阴性4%、正确分类88%。

核心结论

  • ELF单独或联合FIB-4用于普通人群和高危人群肝纤维化筛查,与FIB-4和NFS相比可减少无效转诊,且不漏诊真实病例。

研究设计与样本

  • 前瞻性研究,纳入普通人群及ALD或NAFLD高危人群共3378人(普通人群1973人,ALD高危953人,NAFLD高危452人),中位年龄57岁(IQR 51-63)。
  • 筛查阳性(TE≥8 kPa)者接受肝活检,同时检测ELF、FIB-4和NFS,采用已验证截断值分别为≥9.8、≥1.3、≥-1.45。

主要发现

  • 242人筛查阳性(普通人群3.4%,ALD高危12%,NAFLD高危14%)。
  • TE<8 kPa者中88%ELF也<9.8,但ELF与TE总体相关性差(Spearman rho=0.207)。
  • ELF假阳性率11%,显著低于FIB-4的35%和NFS的45%,同时保持低假阴性率(<8%)。
  • FIB-4后对不确定病例行ELF的策略:假阳性8%,假阴性4%,正确分类88%。
  • 242例筛查阳性者中155例(64%)接受肝活检,其中54例(35%)有晚期纤维化(≥F3)。

关键数值与推荐

  • ELF截断值≥9.8,FIB-4截断值≥1.3,NFS截断值≥-1.45(均为已验证截断值)。
  • 筛查阳性定义为TE≥8 kPa。
  • 晚期纤维化定义为≥F3。

临床怎么用

  • 作者认为ELF单独或联合FIB-4的两步转诊路径可用于初级保健中对人群肝纤维化进行大规模、针对性或机会性筛查。
  • 作者指出该序贯检测策略转诊确认性肝硬度测量的人数少,检出率高,且直接成本低。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: There is a need for accurate biomarkers of fibrosis for population screening of alcohol-related and non-alcoholic fatty liver disease (ALD, NAFLD). We compared the performance of the enhanced liver fibrosis (ELF) test to the fibrosis-4 index (FIB-4) and NAFLD fibrosis score (NFS), using transient elastography as the reference standard. METHODS: We prospectively included participants from the general population, and people at risk of ALD or NAFLD. Screening positive participants (TE ≥8 kPa) were offered a liver biopsy. We measured concomitant ELF, FIB-4, and NFS using validated cut-offs: ≥9.8, ≥1.3, ≥-1.45, respectively. RESULTS: We included 3,378 participants (1,973 general population, 953 at risk of ALD, 452 at risk of NAFLD), with a median age of 57 years (IQR: 51-63). Two hundred-and-forty-two were screening positive (3.4% in the general population, 12%/14% who were at-risk of ALD/NAFLD, respectively). Most participants with TE <8 kPa also had ELF <9.8 (88%) despite a poor overall correlation between ELF and TE (Spearman´s rho = 0.207). ELF was associated with significantly fewer false positives (11%) than FIB-4 and NFS (35% and 45%), while retaining a low rate of false negatives (<8%). A screening strategy of FIB-4 followed by ELF in indeterminate cases resulted in false positives in 8%, false negatives in 4% and the correct classification in 88% of cases. We performed a liver biopsy in 155/242 (64%) patients who screened positive, of whom 54 (35%) had advanced fibrosis (≥F3). ELF diagnosed advanced fibrosis with significantly better diagnostic accuracy than FIB-4 and NFS: AUROC 0.85 (95% CI 0.79-0.92) vs. 0.73 (0.64-0.81) and 0.66 (0.57-0.76), respectively. CONCLUSION: The ELF test alone or combined with FIB-4 for liver fibrosis screening in the general population and at-risk groups reduces the number of futile referrals compared to FIB-4 and NFS, without overlooking true cases. IMPACT AND IMPLICATIONS: We need referral pathways that are efficient at detecting advanced fibrosis from alcohol-related and non-alcoholic fatty liver disease in the population, but without causing futile referrals or excessive use of resources. This study indicates that a sequential test strategy of FIB-4 followed by the ELF test in indeterminate cases leads to few patients referred for confirmatory liver stiffness measurement, while retaining a high rate of detected cases, and at low direct costs. This two-step referral pathway could be used by primary care for mass, targeted, or opportunistic screening for liver fibrosis in the population. CLINICAL TRIAL NUMBER: Clinicaltrials.gov number NCT03308916.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Kjaergaard M, Lindvig KP, Thorhauge KH, et al. Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease. J Hepatol. 2023. PMID: 37088311. doi:10.1016/j.jhep.2023.04.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。